Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus UROVIST CYSTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus UROVIST CYSTO.
CONRAY 43 vs UROVIST CYSTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Urovist Cysto is a radiocontrast agent containing diatrizoate meglumine and diatrizoate sodium. It provides radiographic visualization of the urinary tract by attenuating X-rays due to its iodine content. It is not systemically absorbed when used intravesically; local contrast enhancement occurs through physical properties.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Instillation of 50 mL of a 0.3% solution intravesically, retained for 10 minutes, for cystography.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Primarily renal excretion as unchanged drug (approximately 85-90% within 24 hours); minor biliary/fecal elimination (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent